<DOC>
	<DOCNO>NCT00319865</DOCNO>
	<brief_summary>Prospective multicenter phase 2 study use PAD Thal/Dex combination sequentially .</brief_summary>
	<brief_title>PAD Combination Therapy Followed Thal/Dex Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>Although overall survival improve introduction high dose therapy autologous hematopoetic stem cell transplantation , remain incurable disease . Most patient ultimately relapse . Recenlty , target therapy use novel agent , bortezomib thalidomide , show possibility improve situation . Among , PAD ( Velcade , Adriamycin , Dexamethasone ) show high response rate . PAD show cross resiatance another effective combination , thalidomide plus dexamethasone . We desined prospective multicenter phase 2 study use combination sequentially .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients multiple myeloma relapse least 1 line therapy include high dose thearapy autologous stem cell transplantation chemotherapy . Presence measureble disease : serum Mprotein &gt; 1g/dL urine Mprotein &gt; 400mg/day Age &lt; 75 Performance status &lt; /= ECOG 2 Expected survival &gt; 6 month sign informed consent know hypersensitivity thalidomide dexamethasone know refractoriness thalidomide + dexamethasone Previous Velcade therapy Sepsis Woman reproductive age Serum creatinine &gt; 2 mg/dL ; 24 hour creatinine clearance &lt; 30 ml/min ; past medical history kidney transplatation Peripheral neuropathy &gt; /= grade 2 Recurrent DVT pulmonary embolism Cardiac ejection fraction &lt; 0.5 : Severe conduction disorder Hepatic dysfunction ( AST ALT ≥ x 5 upper normal ) active hepatitis Active ulcer gastrofiberscope</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Multiple Myeloma Relapsed</keyword>
</DOC>